FTC, Amgen/Horizon told to push for in-house trial delay
The Federal Trade Commission’s internal judge has encouraged Amgen, Horizon Therapeutics and agency staff to go ahead with plans to ask the commissioners to delay the administrative case against the drugmakers’ merger.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10